$0.1514
+0.02
(+17.27%)▲
In the last 1 year, Seagen Inc has given 36.8% return, outperforming this stock by 129.7%
In the last 3 years, Moderna Inc has given 23.1% return, outperforming this stock by 119.7%
9.0%
Downside
Day's Volatility :10.49%
Upside
1.64%
83.8%
Downside
52 Weeks Volatility :99.26%
Upside
95.44%
Period | Evelo Biosciences Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -75.88% | 0.3% | -6.7% |
6 Months | -92.85% | -8.3% | -6.2% |
1 Year | -92.88% | -4.8% | -6.3% |
3 Years | -96.56% | 23.8% | 26.9% |
Market Capitalization | 17.0M |
Book Value | - $0.04 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -1.12 |
Wall Street Target Price | 1.4 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -89.02% |
Return On Equity TTM | -6232.76% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -106.4M |
Diluted Eps TTM | -1.12 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.69 |
EPS Estimate Next Year | -0.72 |
EPS Estimate Current Quarter | -0.17 |
EPS Estimate Next Quarter | -0.16 |
What analysts predicted
Upside of 824.7%
Sell
Neutral
Buy
Evelo Biosciences Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Evelo Biosciences Inc | 32.42% | -92.85% | -92.88% | -96.56% | -99.05% |
![]() Moderna, Inc. | -5.37% | -28.24% | -13.14% | 103.02% | 578.71% |
![]() Regeneron Pharmaceuticals, Inc. | -10.19% | -3.62% | 8.99% | 20.86% | 140.79% |
![]() Seagen, Inc. | -2.85% | 59.4% | 42.61% | 23.08% | 240.77% |
![]() Vertex Pharmaceuticals Incorporated | -4.35% | 4.3% | 22.83% | 14.6% | 112.57% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Evelo Biosciences Inc | NA | NA | NA | -0.69 | -62.33 | -0.89 | 0.0 | -0.04 |
![]() Moderna, Inc. | 11.28 | 11.28 | 0.0 | -1.96 | 0.27 | 0.12 | 0.0 | 49.12 |
![]() Regeneron Pharmaceuticals, Inc. | 20.02 | 20.02 | 9.01 | 41.59 | 0.19 | 0.1 | 0.0 | 219.38 |
![]() Seagen, Inc. | NA | NA | 18.53 | -2.88 | -0.23 | -0.12 | 0.0 | 14.54 |
![]() Vertex Pharmaceuticals Incorporated | 27.02 | 27.02 | 0.41 | 14.64 | 0.26 | 0.17 | 0.0 | 56.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Evelo Biosciences Inc | Hold | $14.5M | -99.05% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $48.2B | 578.71% | 11.28 | 31.77% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $79.5B | 140.79% | 20.02 | 33.81% |
![]() Seagen, Inc. | Hold | $36.5B | 240.77% | NA | -31.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $85.7B | 112.57% | 27.02 | 35.4% |
Flagship Ventures Management, Inc.
FMR Inc
State Treasurer State Of Michigan
Credit Suisse First Boston (CSFB)
Vanguard Group Inc
Harbourvest Partners, LLC
Evelo Biosciences Inc’s price-to-earnings ratio stands at None
Read MoreEvelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on the small intestinal axis, SINTAX™, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems. The Company's first product candidates are pharmaceutical preparations of single strains of microbes selected for the potential to offer defined pharmacological properties. Evelo's therapies have the potential to be effective, safe, and affordable medicines to improve the lives of people with inflammatory diseases and cancer.
Organization | Evelo Biosciences Inc |
Employees | 66 |
CEO | Dr. Balkrishan Gill Ph.D. |
Industry | Health Technology |
Presto Automation Inc
$3.59
+63.93%
D-MARKET ELECTRONIC SERVICES
$1.04
+4.0%
Mexico MSCI Capped ETF iShares
$61.22
+2.03%
Global X S&P Catholic Values Developed ex-US ETF
$27.84
+0.0%
IndexIQ ETF Trust - IQ Chaikin U.S. Small Cap ETF
$30.75
+0.5%
DFA Dimensional Internatl High Profitability ETF
$24.08
+1.09%
Precigen Inc
$1.22
+1.67%
EXSCIENTIA PLC
$7.96
+1.14%
ISHARES GEN-IMMUNOLOGY HLTH
$24.03
+0.92%